Evidence map›Paper›PMID 31681618›Full record

ArticleFrontiers in oncology2019

A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy.

Yixin Liu, Zheyang Zhang, Tianhao Li, Xin Li, Sainan Zhang, Ying Li, Wenyuan Zhao, Yunyan Gu, Zheng Guo, Lishuang Qi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Translocon-associated Protein Subunit SSR3 Determines and Predicts Susceptibility to Paclitaxel in Breast Cancer and Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Yixin LiuBasic Medicine College, Harbin Medical University, Harbin, China.
Zheyang ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Tianhao LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Xin LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Sainan ZhangCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Ying LiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Wenyuan ZhaoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Yunyan GuCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Zheng GuoCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Lishuang QiCollege of Bioinformatics Science and Technology, Harbin Medical University, Harbin, China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Resistance to platinum and taxane adjuvant chemotherapy (ACT) is the main cause of the recurrence and poor prognosis of high-grade serous ovarian cancer (HGS-OvCa) patients receiving platinum-taxane ACT after surgery. However, currently reported quantitative transcriptional signatures, which are commonly based on risk scores summarized from gene expression, are unsuitable for clinical application because of their high sensitivity to experimental batch effects and quality uncertainties of clinical samples. Using 226 samples of HGS-OvCa patients receiving platinum-taxane ACT in TCGA, we developed a qualitative transcriptional signature, consisting of four gene pairs whose within-samples relative expression orderings could robustly predict patient recurrence-free survival (RFS). In two independent test datasets, the predicted non-responders had significantly shorter RFS than the predicted responders (log-rank

Indexed as

ovarian cancerplatinum chemotherapypredictive signaturerelative expression orderingstaxane chemotherapy

Identifiers

PMID31681618
PMCPMC6813654
OpenAlexW2980594759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.